Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 Protein Elicits Broadly Neutralizing and Th1-biased Immunoreactivity in Mice

Overview

Journal Int J Biol Macromol

Publisher Elsevier

Date 2021 Nov 14

PMID 34774590

Citations 12

Authors

Hui-Tsu Lin

Cheng-Cheung Chen

Der-Jiang Chiao

Tein-Yao Chang

Xin-An Chen

Jenn-Jong Young

Szu-Cheng Kuo

Affiliations

Soon will be listed here.

Abstract

The spike (S) protein is a leading vaccine candidate against SARS-CoV-2 infection. The S1 domain of S protein, which contains a critical receptor-binding domain (RBD) antigen, potentially induces protective immunoreactivities against SARS-CoV-2. In this study, we presented preclinical evaluations of a novel insect cell-derived SARS-CoV-2 recombinant S1 (rS1) protein as a potent COVID-19 vaccine candidate. The native antigenicity of rS1 was characterized by enzyme-linked immunosorbent assay with a neutralizing monoclonal antibody targeting the RBD antigen. To improve its immunogenicity, rS1-adjuvanted with fucoidan/trimethylchitosan nanoparticles (FUC-TMC NPs) and cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-ODNs) were investigated using a mouse model. The S1-specific immunoglobulin G (IgG) titers, FluoroSpot assay, pseudovirus- and prototype SARS-CoV-2-based neutralization assays were assessed. The results showed that the rS1/CpG/ FUC-TMC NPs (rS1/CpG/NPs) formulation induced a broad-spectrum IgG response with potent, long-lasting, and cross-protective neutralizing activity against the emerging SARS-CoV-2 variant of concern, along with a Th1-biased cellular response. Thus, the rS1/CpG/NPs formulation presents a promising vaccination approach against COVID-19.

Citing Articles

Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.

Ji J, Chen L, Wu Z, Tang T, Zhu L, Zhu M Sci Rep. 2024; 14(1):31424.

PMID: 39733119 PMC: 11682164. DOI: 10.1038/s41598-024-83026-x.

The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2.

Hu Y, Liu L, Zhang S, Su S, Liang X ACS Omega. 2024; 9(5):5175-5192.

PMID: 38343922 PMC: 10851365. DOI: 10.1021/acsomega.3c08326.

Nasal Administration of M2e/CpG-ODN Encapsulated in N-Trimethyl Chitosan (TMC) Significantly Increases Specific Immune Responses in a Mouse Model.

Taghizadeh M, Dabaghian M Arch Razi Inst. 2023; 77(6):2259-2268.

PMID: 37274902 PMC: 10237570. DOI: 10.22092/ARI.2022.360447.2583.

A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice.

Song Y, Hu H, Xiao K, Huang X, Guo H, Shi Y Microbiol Spectr. 2023; :e0419422.

PMID: 36912685 PMC: 10100915. DOI: 10.1128/spectrum.04194-22.

Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.

Li Y, McGowan E, Chen S, Santos J, Yin H, Lin Y Mar Drugs. 2023; 21(2).

PMID: 36827169 PMC: 9961398. DOI: 10.3390/md21020128.

References

Wibmer C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4):622-625. DOI: 10.1038/s41591-021-01285-x. View

Jaimes J, Andre N, Chappie J, Millet J, Whittaker G . Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. J Mol Biol. 2020; 432(10):3309-3325. PMC: 7166309. DOI: 10.1016/j.jmb.2020.04.009. View

Pack D, Hoffman A, Pun S, Stayton P . Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005; 4(7):581-93. DOI: 10.1038/nrd1775. View

Zhang H, Gao X . Nanodelivery systems for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides. Mater Sci Eng C Mater Biol Appl. 2016; 70(Pt 2):935-946. DOI: 10.1016/j.msec.2016.03.045. View

Shi X, Jarvis D . Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets. 2007; 8(10):1116-25. PMC: 3647355. DOI: 10.2174/138945007782151360. View

Wen Z, Xu Y, Zou X, Xu Z . Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs. 2011; 9(6):1038-1055. PMC: 3131560. DOI: 10.3390/md9061038. View

Lai C, To A, Wong T, Lieberman M, Clements D, Senda J . Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. Vaccine X. 2021; :100126. PMC: 8570651. DOI: 10.1016/j.jvacx.2021.100126. View

Tsai M, Chuang C, Chen C, Yen H, Cheng K, Chen X . Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG. Carbohydr Polym. 2020; 236:116041. DOI: 10.1016/j.carbpol.2020.116041. View

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

10.

Zaharoff D, Rogers C, Hance K, Schlom J, Greiner J . Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 2007; 25(11):2085-94. PMC: 1890043. DOI: 10.1016/j.vaccine.2006.11.034. View

11.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

12.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

13.

Farhadian A, Mohammadpour Dounighi N, Avadi M . Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery. Hum Vaccin Immunother. 2015; 11(12):2811-8. PMC: 5054785. DOI: 10.1080/21645515.2015.1053663. View

14.

Kim E, Erdos G, Huang S, Kenniston T, Balmert S, Donahue Carey C . Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:102743. PMC: 7128973. DOI: 10.1016/j.ebiom.2020.102743. View

15.

Nguyen D, Green J, Chan J, Longer R, Anderson D . Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater. 2017; 21(8):847-867. PMC: 5391878. DOI: 10.1002/adma.200801478. View

16.

Verheul R, Hagenaars N, van Es T, van Gaal E, de Jong P, Bruijns S . A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine. Eur J Pharm Sci. 2011; 45(4):467-74. DOI: 10.1016/j.ejps.2011.10.001. View

17.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

18.

Walls A, Fiala B, Schafer A, Wrenn S, Pham M, Murphy M . Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020; 183(5):1367-1382.e17. PMC: 7604136. DOI: 10.1016/j.cell.2020.10.043. View

19.

Hanagata N . Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine. 2012; 7:2181-95. PMC: 3356174. DOI: 10.2147/IJN.S30197. View

20.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View